Hospital of the University of Pennsylvania-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2018

  1. Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN study

    Journal of Clinical Oncology, Vol. 36, Núm. 23, pp. 2405-2412